Aceclofenac/eperisone

Drug Profile

Aceclofenac/eperisone

Alternative Names: Eperisone/aceclofenac; HCP-1104

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Esters; Muscle relaxants; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenylacetates; Piperidines; Propiophenones; Small molecules
  • Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Back pain

Most Recent Events

  • 17 Feb 2016 Discontinued - Phase-II for Back pain in South Korea (PO)
  • 01 Jul 2013 Hanmi Pharmaceutical completes its phase II trial in Back pain in South Korea (NCT01806818)
  • 03 Jun 2013 Hanmi Pharmaceutical plans a phase I trial in healthy volunteers in South Korea (NCT01869985)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top